(Recasts; adds details)
Oct 27 Barr Pharmaceuticals Inc BRL.N said the U.S. regulators approved an oral contraceptive made by its unit Duramed Pharmaceuticals Inc.
Barr, which agreed to be bought by Israel-based Teva Pharmaceutical Industries Ltd TEVA.O for $7.46 billion in July, said the drug, LoSeasonique, would be available by prescription to women in the first quarter of 2009. The drug's extended-cycle regimen, indicated for prevention of pregnancy, is designed to reduce the number of withdrawal bleeding periods from 13 to four per year, the company said in a statement.
Withdrawal bleeding is experienced each month when a woman uses a hormonal birth control method.
Shares of Barr were down 56 cents at $58.58 in early morning trade on the New York Stock Exchange. (Reporting by Esha Dey in Bangalore; Editing by Anil D'Silva;)